Fluticasone propionate/glycopyrronium bromide/salmeterol xinafoateAlternative Names: PSX 3001
Latest Information Update: 20 Jan 2017
At a glance
- Originator Prosonix
- Developer Circassia
- Class Anti-inflammatories; Antiasthmatics; Antibronchitics; Antispasmodics; Bronchodilators; Glucocorticoids; Phenethylamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists; Steroid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease